Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.

European journal of clinical pharmacology - 1 Feb 2012

Choi Chang-Ik, Kim Mi-Jeong, Chung Eun-Kyung, Lee Hye-In, Jang Choon-Gon, Bae Jung-Woo, Lee Seok-Yong

Abstract excerpt

PURPOSE: To evaluate the effects of two major polymorphisms of CYP2C9, CYP2C9 3 and CYP2C9 13, on the pharmacokinetics of irbesartan in healthy Korean volunteers. METHODS: A single 150-mg oral dose of irbesartan was given to 28 Korean volunteers, who had different CYP2C9 genotypes (12, 10, and 6 carriers of CYP2C9 1/ 1, 1/ 3, and 1/13 genotypes respectively). Irbesartan levels were analyzed using HPLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Aryl Hydrocarbon Hydroxylases

Share to Biphenyl Compounds

Share to Cytochrome P-450 CYP2C9

Share to Half-Life

Share to Tetrazoles

Source

Identifiers

PMID: 21842338
DOI: 10.1007/s00228-011-1098-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.PMID 21842338Read ↗

CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Semantic proximity Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.Semantic proximity Read ↗

Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.Semantic proximity Read ↗

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.Semantic proximity Read ↗

CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.Semantic proximity Read ↗

Allele and genotype frequencies of CYP2C9 in a Korean populationSemantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.Semantic proximity Read ↗

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.